Depressive-like symptoms in a reserpine-induced model of fibromyalgia in rats

Physiology and Behavior

Volumn 151, Issue , 2015, Pages 456-462

  Blasco Serra, Arantxa ^a   Escrihuela Vidal, Francesc ^a   González Soler, Eva M ^a   Martínez Expósito, Fernando ^a   Blasco Ausina, Ma Carmen ^a   Martínez Bellver, Sergio ^a   Cervera Ferri, Ana ^a   Teruel Martí, Vicent ^a   Valverde Navarro, Alfonso A ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Animal pain model; Depression; Fibromyalgia; Novelty Suppressed Feeding Test; Reserpine

Indexed keywords

RESERPINE; ADRENERGIC RECEPTOR AFFECTING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; FIBROMYALGIA; FOOD DEPRIVATION; MALE; MONOAMINERGIC SYSTEM; MUSCULOSKELETAL PAIN; NONHUMAN; NOVELTY SUPPRESSED FEEDING TEST; PAIN THRESHOLD; PREVALENCE; PRIORITY JOURNAL; RAT; SMELLING; TASK PERFORMANCE; VON FREY TEST; ANIMAL; CHEMICALLY INDUCED; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; EXPLORATORY BEHAVIOR; FEEDING BEHAVIOR; IMMOBILIZATION; INHIBITION (PSYCHOLOGY); MOTOR ACTIVITY; SPRAGUE DAWLEY RAT; TIME FACTOR;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; DEPRESSION; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; FEEDING BEHAVIOR; FIBROMYALGIA; HINDLIMB SUSPENSION; INHIBITION (PSYCHOLOGY); MALE; MOTOR ACTIVITY; PAIN THRESHOLD; RATS; RATS, SPRAGUE-DAWLEY; RESERPINE; TIME FACTORS;

EID: 84939809976     PISSN: 00319384     EISSN: 1873507X     Source Type: Journal    
DOI: 10.1016/j.physbeh.2015.07.033     Document Type: Article

References (62)

1. Bellato E., Marini E., Castoldi F., Barbasetti N., Mattei L., Bonasia D.E., Blonna D. Fibromyalgia syndrome: etiology, pathogenesis, diagnosis, and treatment. Pain Res Treat 2012, 2012:426130. 10.1155/2012/426130.
2. Wolfe F., Brähler E., Hinz A., Häuser W. Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population. Arthritis Care Res. 2013, 65(5):777-785. 10.1002/acr.21931.
3. Häuser W., Urrútia G., Tort S., Üçeyler N., Walitt B. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database Syst. Rev. 2012, 1:CD010292-2. 10.1002/14651858.
4. DeSantana J.M., da Cruz K.M., Sluka K.A. Animal models of fibromyalgia. Arthritis Res. Ther. 2013, 15(6):222.
5. Kehl L.J., Trempe T.M., Hargreaves K.M. A new animal model for assessing mechanisms and management of muscle hyperalgesia. Pain 2000, 85(3):333-343.
6. Sluka K.A., Kalra A., Moore S.A. Unilateral intramuscular injections of acidic saline produce a bilateral, long-lasting hyperalgesia. Muscle Nerve 2000, 24(1):37-46.
7. Schäfers M., Sorkin L.S., Sommer C. Intramuscular injection of tumor necrosis factor-alpha induces muscle hyperalgesia in rats. Pain 2003, 104(3):579-588.
8. Furuta A., Suzuki Y., Honda M., Koike Y., Naruoka T., Asano K., Chancellor M., Egawa S., Yoshimura N. Time-dependent changes in bladder function and plantar sensitivity in a rat model of fibromyalgia syndrome induced by hydrochloric acid injection into the gluteus. BJU Int. 2011, 109(2):306-310. 10.1111/j.1464-410X.2011.10258.x.
9. Quintero L., Cardenas R., Suarez-Roca H. Stress-induced hyperalgesia is associated with a reduced and delayed GABA inhibitory control that enhances post-synaptic NMDA receptor activation in the spinal cord. Pain 2011, 152(8):1909-1922. 10.1016/j.pain.2011.04.017.
10. Green P.G., Alvarez P., Gear R.W., Mendoza D., Levine J.D. Further validation of a model of fibromyalgia syndrome in the rat. J Pain. 2011, 12(7):811-818. 10.1016/j.jpain.2011.01.006.
11. Consoli G., Marazziti D., Ciapparelli A., Bazzichi L., Massimetti G., Giacomelli C., Rossi A., Bombardieri S., Dell'Osso L. The impact of mood, anxiety, and sleep disorders on fibromyalgia. Compr. Psychiatry 2012, 53(7):962-967. 10.1016/j.comppsych.2012.03.008.
12. Ohayon M.M. Pain sensitivity, depression, and sleep deprivation: links with serotoninergic dysfunction. J. Psychiatr. Res. 2009, 43(16):1243-1245. 10.1016/j.jpsychires.2009.10.007.
13. Dunne F.J.F., Dunne C.A.C. Fibromyalgia syndrome and depression: common pathways. Br J Hosp Med (Lond). 2012, 73(4):211-217.
14. Becker S., Schweinhardt P. Dysfunctional neurotransmitter systems in fibromyalgia, their role in central stress circuitry and pharmacological actions on these systems. Pain Res Treat 2012, 2012:761746. 10.1155/2012/741746.
15. Koyama Y. Regulation of sleep and wakefulness through the monoaminergic and cholinergic systems. Brain Nerve. 2012, 64(6):601-610.
16. Petersel D.L., Dror V., Cheung R. Central amplification and fibromyalgia: disorder of pain processing. J. Neurosci. Res. 2011, 89(1):29-34. 10.1002/jnr.22512.
17. Buskila D., Sarzi-Puttini P., Ablin J.N. The genetics of fibromyalgia syndrome. Pharmacogenomics 2007, 8(1):67-74.
18. Munro G. Comment on Biogenic amine depletion as a putative animal model of fibromyalgia [Pain 2009;146:26-33]. Pain. 148(1):172-3. doi:. doi:10.1016/j.pain.2009.10.018.
19. Samuels BA, Hen R. (2011). Novelty-suppressed feeding in the mouse. In: Todd D. Gould (Ed.). Mood and Anxiety Related Phenotypes in Mice: Characterization Using Behavioral Tests, Volume II. 63:107-21. Neuromethods. Totowa, NJ: Humana Press. doi:. doi:10.1007/978-1-61779-313-4_7.
20. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 16(2):109-110.
21. Schmitt U., Hiemke C. Strain differences in open-field and elevated plus-maze behavior of rats without and with pretest handling. Pharmacol. Biochem. Behav. 1998, 59(4):807-811.
22. Nagakura Y., Oe T., Aoki T., Matsuoka N. Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: a putative animal model of fibromyalgia. Pain 2009, 146(1-2):26-33. 10.1016/j.pain.2009.05.024.
23. Colpaert F.C. Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat. Neuropharmacology 1987, 26:1431-1440.
24. Oe T., Tsukamoto M., Nagakura Y. Reserpine causes biphasic nociceptive sensitivity alteration in conjunction with brain biogenic amine tones in rats. Neuroscience 2010, 169(4):1860-1871. 10.1016/j.neuroscience.2010.06.061.
25. Wang Y., Chang T., Chen Y.-C., Zhang R.-G., Wang H.-N., Wu W.-J., Peng Z.-W., Tan Q.-R. Quetiapine add-on therapy improves the depressive behaviors and hippocampal neurogenesis in fluoxetine treatment resistant depressive rats. Behav. Brain Res. 2013, 253:206-211. 10.1016/j.bbr.2013.07.021.
26. Fietta P., Fietta P., Manganelli P. Fibromyalgia and psychiatric disorders. Acta Biomed. 2007, 78(2):88-95.
27. Agüera-Ortiz L., Failde I., Mico J.A., Cervilla J., López-Ibor J.J. Pain as a symptom of depression: prevalence and clinical correlates in patients attending psychiatric clinics. J. Affect. Disord. 2011, 130(1-2):106-112. 10.1016/j.jad.2010.10.022.
28. Wolfe F., Clauw D.J., Fitzcharles M.-A., Goldenberg D.L., Katz R.S., Mease P., Russell A.S., Russell I.J., Winfield J.B., Yunus M.B. The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity. Arthritis Care Res. 2010, 62(5):600-610. 10.1002/acr.20140.
29. Dulawa S.C., Hen R. Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test. Neurosci. Biobehav. Rev. 2005, 29(4-5):771-783.
30. Stedenfeld K.A., Clinton S.M., Kerman I.A., Akil H., Watson S.J., Sved A.F. Novelty-seeking behavior predicts vulnerability in a rodent model of depression. Physiol. Behav. 2011, 103(2):210-216. 10.1016/j.physbeh.2011.02.001.
31. Nestler E.J., Hyman S.E. Animal models of neuropsychiatric disorders. Nat. Neurosci. 2010, 13(10):1161-1169. 10.1038/nn.2647.
32. David D.J., Samuels B.A., Rainer Q., Wang J.-W., Marsteller D., Mendez I., Drew M., Craig D.A., Guiard B.P., Guilloux J.-P., Artymyshyn R.P., Gardier A.M., Gerald C., Antonijevic I.A., Leonardo E.D., Hen R. Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. Neuron 2009, 62(4):479-493. 10.1016/j.neuron.2009.04.017.
33. Surget A., Saxe M., Leman S., Ibarguen-Vargas Y., Chalon S., Griebel G., Hen R., Belzung C. Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal. Biol. Psychiatry 2008, 64(4):293-301. 10.1016/j.biopsych.2008.02.022.
34. Nagakura Y., Takahashi M., Noto T., Sekizawa T., Oe T., Yoshimi E., Tamaki K., Shimizu Y. Different pathophysiology underlying animal models of fibromyalgia and neuropathic pain: comparison of reserpine-induced myalgia and chronic constriction injury rats. Behav. Brain Res. 2012, 226(1):242-249. 10.1016/j.bbr.2011.09.023.
35. De Souza A.H., da Costa Lopes A.M., Castro C.J., Pereira E.M.R., Klein C.P., da Silva C.A., da Silva J.F., Ferreira J., Gomez M.V. The effects of Phα1β, a spider toxin, calcium channel blocker, in a mouse fibromyalgia model. Toxicon 2014, 81:37-42. 10.1016/j.toxicon.2014.01.015.
36. Klein C.P., Sperotto N.D.M., Maciel I.S., Leite C.E., Souza A.H., Campos M.M. Effects of D-series resolvins on behavioral and neurochemical changes in a fibromyalgia-like model in mice. Neuropharmacology 2014, 86:57-66. 10.1016/j.neuropharm.2014.05.043.
37. Taguchi T., Katanosaka K., Yasui M., Hayashi K., Yamashita M., Wakatsuki K., Kiyama H., Yamanaka A., Mizumura K. Peripheral and spinal mechanisms of nociception in a rat reserpine-induced pain model. Pain 2015, 156(3):415-427. 10.1097/01.j.pain.0000460334.49525.5e.
38. Nammi S., Boini K.M., Koppula S., Sreemantula S. Reserpine-induced central effects: pharmacological evidence for the lack of central effects of reserpine methiodide. Can. J. Physiol. Pharmacol. 2005, 83(6):509-515.
39. Calderon J.L., Bolaños R., Carrillo J.D., Escamilla C., Salazar S., Moreno G., Rivera G. Behavioral analysis of the reserpine induced motor changes in a Parkinsonian mouse model. Revista Neuropsicología, Neuropsiquiatría y Neurociencias 2011, 11(2):49-61.
40. Legangneux E., Mora J.J., Spreux Varoquaux O., Thorin I., Herrou M., Alvado G., Gomeni C. Cerebrospinal fluid biogenic amine metabolites, plasma-rich platelet serotonin and [3H] imipramine reuptake in the primary fibromyalgia syndrome. Rheumatology 2001, 40(3):290-296.
41. Dadabhoy D., Crofford L.J., Spaeth M., Russell I.J., Clauw D.J. Biology and therapy of fibromyalgia. Evidence-based biomarkers for fibromyalgia syndrome. Arthritis Res. Ther. 2008, 10(4):211. (Epub 2008 Aug 8). 10.1186/ar2443.
42. Buskila D. Developments in the scientific and clinical understanding of fibromyalgia. Arthritis Res. Ther. 2009, 11(5):242. (Epub 2009 Oct 14). 10.1186/ar2720.
43. Arora V., Kuhad A., Tiwari V., Chopra K. Curcumin ameliorates reserpine-induced pain-depression dyad: behavioural, biochemical, neurochemical and molecular evidences. Psychoneuroendocrinology 2011, 36(10):1570-1581.
44. Yunus M.B. Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. Semin. Arthritis Rheum. 2007, 36(6):339-356.
45. Akiskal H.S., McKinney W.T. Depressive disorders: toward a unified hypothesis: clinical, experimental, genetic, biochemical, and neurophysiological data are integrated. Science 1973, 182:20-29.
46. Elhwuegi A.S. Central monoamines and their role in major depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2004, 28(3):435-451.
47. Hamon M., Blier P. Monoamine neurocircuitry in depression and strategies for new treatments. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2013, 45:54-63. 10.1016/j.pnpbp.2013.04.009.
48. Baumeister A.A., Hawkins M.F., Uzelac S.M. The myth of reserpine-induced depression: role in the historical development of the monoamine hypothesis. J. Hist. Neurosci. 2003, 12(2):207-220.
49. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., Monteggia L.M. Neurobiology of depression. Neuron 2002, 34(1):13-25.
50. Kalia M. Neurobiological basis of depression: an update. Metabolism 2005, 54(5 suppl 1):24-27.
51. Ponzio F., Achilli G., Calderini G., Ferretti P., Perego C., Toffano G., Algeri S. Depletion and recovery of neuronal monoamine storage in rats of different ages treated with reserpine. Neurobiol. Aging 1984, 5(2):101-104.
52. Minor T.R., Huang Q., Foley E.A. Cytokine-purine interactions in behavioral depression in rats. Integr. Physiol. Behav. Sci. 2003, 38(3):189-202.
53. Hanff T.C., Furst S.J., Minor T.R. Biochemical and anatomical substrates of depression and sickness behavior. Isr J Psychiatry Relat Sci. 2010, 47(1):64-71.
54. Antkiewicz-Michaluk L., Wąsik A., Moz˙dz˙eń E., Romańska I., Michaluk J. Withdrawal from repeated administration of a low dose of reserpine induced opposing adaptive changes in the noradrenaline and serotonin system function: a behavioral and neurochemical ex vivo and in vivo studies in the rat. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2015, 57:146-154. 10.1016/j.pnpbp.2014.10.009.
55. Minor T.R., Hanff T.C. Adenosine signaling in reserpine-induced depression in rats. Behav. Brain Res. 2015, 286:184-191. 10.1016/j.bbr.2015.02.032.
56. Sluka K.A. Is it possible to develop an animal model of fibromyalgia?. Pain 2009, 146(1-2):3-4. 10.1016/j.pain.2009.07.032.
57. Wolfe F., Ross K., Anderson J., Russell I.J. Aspects of fibromyalgia in the general population: sex, pain threshold, and fibromyalgia symptoms. J Rheumatol. 1995, 22(1):151-156.
58. Jones G.T., Atzeni F., Beasley M., Flüß E., Sarzi-Puttini P., Macfarlane G.J. The prevalence of fibromyalgia in the general population: a comparison of the American College of Rheumatology 1990, 2010, and modified 2010 classification criteria. Arthritis Rheum. 2015, 67(2):568-575. 10.1002/art.38905.
59. Slattery D.A., Cryan J.F. The ups and downs of modelling mood disorders in rodents. ILAR J. 2014, 55(2):297-309. 10.1093/ilar/ilu026.
60. Fillingim R.B., Ness T.J. Sex-related hormonal influences on pain and analgesic responses. Neurosci. Biobehav. Rev. 2000, 24(4):485-501.
61. Aloisi AM, Bonifazi M. (2006). Sex hormones, central nervous system and pain. Horm. Behav. 50(1):1-7.
62. Okifuji A., Turk D.C. Sex hormones and pain in regularly menstruating women with fibromyalgia syndrome. J Pain. 2006, 7(11):851-859.